A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

Phase 2 Completed 431 enrolled Kallyope Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.

Timeline

Start: 2025-03-11
Primary completion: 2025-08-04
Completion: 2025-08-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Elismetrep	Small molecule	2 mg	Oral
Subject	Elismetrep	Small molecule	5 mg	Oral
Subject	Elismetrep	Small molecule	10 mg	Oral
Subject	Elismetrep	Small molecule	20 mg	Oral

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

Summary

Timeline

Drugs

Indications